Mavyret (glecaprevir+pibrentasvir). Its psoriasis drug risankizumab is under review with the FDA after strong phase 3 results and could be launched next year if things go well with the regulator.

Since 1992, the inclusion of HBV vaccination has been recommended by the WHO for all immunization programs implemented by nations. In Europe, the introduction of HBV vaccination has markedly ...

The management of chronic hepatitis B (CHB) during pregnancy remains a challenge and involves various aspects of maternal-fetal care. Despite the standard immunoprophylaxis, a significant portion ...